Christine Dienna, DO
Cardiovascular Disease · Oklahoma City, OKNPI 1720313901
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,233 of the $6,476 with a category attached, or 65.4%. 17 manufacturers reported payments, led by Abbott at 38.7% of the total. Reporting peaked in 2019 at $2,234 and has fallen 68.5% since, to $703 in 2025.
Across 116 payments — averaging $55.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Medtronic$1K
- E.r. Squibb & Sons, L.L.C.$848
- Amgen$688
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$385
- Pfizer$175
- plus $536 from 11 others
Across 1 payment — averaging $15,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$15K
What the payments were for
- Travel & lodging$2,23134%
- Food & beverage$4,23365%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 30 | $2,504 |
| Medtronic | 6 | $1,340 |
| E.r. Squibb & Sons, L.L.C. | 14 | $848 |
| Amgen | 26 | $688 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $385 |
| Pfizer | 5 | $175 |
| Novartis | 8 | $140 |
| Sanofi-aventis U.S. LLC | 2 | $136 |
| Boston Scientific | 4 | $95 |
| Amarin Pharma, Inc. | 2 | $34 |
| Irhythm Technologies, Inc. | 1 | $26 |
| Boehringer Ingelheim | 1 | $25 |
| Johnson & Johnson | 1 | $23 |
| AstraZeneca | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Allure CRT Pacemaker$1,235
- Micra$987
- CAMZYOS$470
- Repatha$248
- CardioMEMS HF System$141
- Assurity Pacemaker$138
- CARDIOMEMS$131
- Quadra Assura CRT Defibrillator$123
- DISEASE STATE$123
- Confirm Rx$117
How this compares
$6,476 in reported general payments places this provider in the 75th percentile of 164 cardiovascular disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 82 | $55,589 |
| EliquisApixaban | 50 | $44,194 |
| EntrestoSacubitril/Valsartan | 38 | $27,127 |
| JardianceEmpagliflozin | 22 | $25,811 |
| FarxigaDapagliflozin Propanediol | 25 | $24,722 |
| Praluent PenAlirocumab | 13 | $13,999 |
| XareltoRivaroxaban | 16 | $12,963 |
| VascepaIcosapent Ethyl | 21 | $9,249 |
| BrilintaTicagrelor | 12 | $7,811 |
| Rosuvastatin Calcium | 272 | $2,423 |
| Ranolazine ErRanolazine | 40 | $2,049 |
| Diltiazem 24hr Er (La)Diltiazem Hcl | 14 | $1,159 |
| Ezetimibe | 66 | $1,158 |
| Torsemide | 20 | $1,000 |
| Atorvastatin Calcium | 89 | $767 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $175 | $44,19450 claims |
| AstraZenecaFarxiga, Brilinta | $17 | $32,53237 claims |
| NovartisEntresto | $140 | $27,12738 claims |
| Boehringer IngelheimJardiance | $25 | $25,81122 claims |
| Johnson & JohnsonXarelto | $23 | $12,96316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 164 cardiovascular disease providers in Oklahoma.
Other cardiovascular disease in Oklahoma City
- Aly El BanayosyOklahoma City$54K
- Dwight ReynoldsOklahoma City$47K
- Udho ThadaniOklahoma City$41K
- Robert SullivanOklahoma City$36K
- Reji PappyOklahoma City$25K
- Sandeep ChopraOklahoma City$15K
- Jered CookOklahoma City$14K
- William CollazoOklahoma City$11K
- Vinodh JeevananthamOklahoma City$11K
- Niraj PrasadOklahoma City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.